FAK

FAK Inhibitor 6 specifically targets focal adhesion kinase (FAK) and is recognized for its potent inhibitory effects, with an IC50 of 28.2 nM. This compound demonstrates reduced cytotoxicity (IC50 = 3.32 µM) while effectively inducing apoptosis in MDA-MB-231 breast cancer cells in a dose-dependent manner. Additionally, FAK Inhibitor 6 effectively halts the cell cycle progression of MDA-MB-231 cells at the G0/G1 phase, making it a valuable tool for research in cancer biology and therapeutic development.

ZINC09875266 is a dual inhibitor that specifically targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Focal Adhesion Kinase (FAK). This compound demonstrates potent inhibitory activity that can suppress angiogenesis and cancer cell proliferation. Research applications include studying tumor growth and metastasis in various cancer models.

FAK Inhibitor 5 is a novel allosteric inhibitor of focal adhesion kinase (FAK) that exhibits efficient modulation of FAK activity with IC50 values in the low micromolar range. This compound is utilized in research focusing on cancer biology, cell adhesion, and migration, making it a valuable tool for studying pathways involving FAK signaling. Its specificity allows for detailed investigations into the role of FAK in various cellular processes and disease states.

FAK-IN-16 is a selective inhibitor of focal adhesion kinase (FAK) that exhibits an exceptionally low IC50 of 1.2 pM. This compound effectively inhibits FAK phosphorylation at both pFAK[Y397] and pFAK[Y861], resulting in decreased tumor growth and reduced vascularity and invasiveness. Additionally, FAK-IN-16 enhances the effects of Cisplatin on tumor cell proliferation and apoptosis in vitro, as well as its anti-tumor properties in murine models. This reagent is valuable for researchers focusing on cancer therapy and tumor biology.

FAK-IN-8 is a potent inhibitor of Focal Adhesion Kinase (FAK) with an IC50 value of 5.32 µM. It exhibits significant anti-proliferative activity, making it a valuable tool for cancer research. This compound can be utilized to explore the role of FAK in tumor progression and metastasis, as well as in the development of targeted therapies.

FAK/Aurora kinase-IN-1 is a dual inhibitor targeting focal adhesion kinase (FAK) and Aurora kinase, exhibiting IC50 values of 6.61 nM and 0.91 nM, respectively. This compound demonstrates significant anticancer activity, making it a valuable tool for research applications focused on cancer biology and therapeutic development. Its efficacy in inhibiting both kinases positions it as a promising candidate for further studies in tumor proliferation and treatment strategies.

FAK-IN-10 is a potent inhibitor of focal adhesion kinase (FAK) with an IC50 of 76.3 µM. This compound demonstrates significant antitumor activity, particularly against the MCF-7 and A431 cell lines, exhibiting IC50 values of 4.23 µM and 0.78 µM, respectively. FAK-IN-10 is valuable for research focused on cancer therapeutics and the modulation of signaling pathways associated with tumor growth and metastasis.